Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591725 | 0.98 | HTT (0.47) | HTTGNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL14255477 | 0.82 | CA12 (0.55) | HTTALDH1A1LMNAMAPK1 | |
| SCHEMBL3879759 | 0.82 | GNAI3 (0.50) | HTTGNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL20111517 | 0.80 | GNAI3 (0.62) | HTTGNAI3GNAO1GNAI1ATM | |
| SCHEMBL5743453 | 0.80 | CYP2D6 (0.44) | HTTGNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL8054253 | 0.80 | CYP2D6 (0.46) | HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL2364252 | 0.80 | TP53 (0.50) | HTTGNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL493880 | 0.80 | TP53 (0.50) | HTTGNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL915516 | 0.79 | L3MBTL1 (0.40) | HTTGNAI3GNAO1GNAI1L3MBTL1 | |
| Benzenemethanethiol SCHEMBL7374376 | 0.79 | HTT (0.46) | HTTPOLBMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109923114-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2019-06-21 | — | — | CN | claimed |
| EP-0794827-B1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2002-07-10 | — | — | EP | claimed |
| US-6090252-A | NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY | PHARMACIA BIOTECH AB (SE) | 2000-07-18 | — | — | US | claimed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-0794827-B1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2002-07-10 | — | — | EP | disclosed |
| US-6090252-A | NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY | PHARMACIA BIOTECH AB (SE) | 2000-07-18 | — | — | US | disclosed |
| EP-0794827-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | Pharmacia Biotech AB (SE) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016724-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | PHARMACIA BIOTECH AB (SE) | 1996-06-06 | — | — | WO | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | HTT 582/4885GNAI3 1270/4885GNAO1 980/4885 |
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | HTT 1418/4885GNAI3 627/4885GNAO1 528/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | HTT 160/4885GNAI3 3256/4885GNAO1 1521/4885 |
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | HTT 545/4885GNAI3 895/4885GNAO1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.